Caplacizumab, カプラシズマブ Cablivi is the first therapeutic approved in Europe, for the treatment of a rare blood-clotting disorder

It’s only fair to share… Cablivi is the first therapeutic approved in Europe, for the treatment of a rare blood-clotting disorder On September 03, 2018, the European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is …

USFDA approval to Lumoxiti (moxetumomab pasudotoxtdfk) a new treatment for hairy cell leukemia

It’s only fair to share… USFDA approval to Lumoxiti is a new treatment for hairy cell leukemia On September 13, 2018, the U.S. Food and Drug Administration approved Lumoxiti (moxetumomab pasudotoxtdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory Hairy Cell Leukemia (HCL) who have received at least two …

CIFORADENANT

It’s only fair to share… CIFORADENANT 1202402-40-1 Chemical Formula: C20H21N7O3 Molecular Weight: 407.434 CPI-444, CPI 444, CPI444, V81444, V-81444, V 81444, UNII 8KFO2187CP  Corvus Pharmaceuticals, Inc. PHASE 1 (S)-7-(5-methylfuran-2-yl)-3-((6-(((tetrahydrofuran-3-yl)oxy)methyl)pyridin-2-yl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-5-AMINE, 7-(5-METHYL-2-FURANYL)-3-((6-((((3S)-TETRAHYDRO-3-FURANYL)OXY)METHYL)-2-PYRIDINYL)METHYL)- (73 S)-15 -methyl-6-oxa-2(7,3)-[1,2,3]triazolo[4,5- d]pyrimidina-4(2,6)-pyridina-1(2)-furana-7(3)- oxolanaheptaphan-25 -amine adenosine receptor antagonist Ciforadenant, also known as CPI-444 and V81444, is an orally administered antagonist of the adenosine A2A receptor. …

Netarsudil, Нетарсудил , نيتارسوديل , 奈舒地尔 , ネタルスジル ,

It’s only fair to share… Netarsudil Molecular Formula: C28H27N3O3 Molecular Weight: 453.542 g/mol Netarsudil; UNII-W6I5QDT7QI; W6I5QDT7QI; 1254032-66-0; Netarsudil [USAN]; AR-11324 free base 1422144-42-0 (mesylate)   1254032-66-0 (free base)   1253952-02-1 (HCl) [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate 4-[(2S)-3-Amino-1-(6-isoquinolinylamino)-1-oxo-2-propanyl]benzyl 2,4-dimethylbenzoate [ACD/IUPAC Name] Benzoic acid, 2,4-dimethyl-, [4-[(1S)-1-(aminomethyl)-2-(6-isoquinolinylamino)-2-oxoethyl]phenyl]methyl ester W6I5QDT7QI Нетарсудил [Russian] [INN] نيتارسوديل [Arabic] [INN] 奈舒地尔 [Chinese] [INN] ネタルスジル; Inventor – Aerie Pharmaceuticals, Inc.  Approved by US-FDA in December-2017 for dimesylate salt AR …

Molidustat

It’s only fair to share… Molidustat UNII-9JH486CZ13, cas no 1154028-82-6, MW: 314.3076 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Originator Bayer Schering Pharma Developer Bayer HealthCare Pharmaceuticals Class Antianaemics; Morpholines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules; Triazoles Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors Phase III Anaemia 24 Jun 2018 Biomarkers information updated 23 Jun 2018 Bayer initiates enrolment in the MIYABI HD-M phase III …

BMS 986142

It’s only fair to share… BMS-986142 (2S,5R,3S)-6-fluoro-5-(3-(8-fluoro-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-2-methylphenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-l-methyl-2,4-dioxo-l,2-dihydroquinazolin-3(4H)-yl)-2- methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-lH-carbazole-8- carboxamide Molecular Formula, C32-H30-F2-N4-O4, Molecular Weight, 572.609, RN: 1643368-58-4 UNII: PJX9GH268R Originator Bristol-Myers Squibb Class Anti-inflammatories; Antirheumatics; Small molecules Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors Phase II Rheumatoid arthritis; Sjogren’s syndrome 24 Jun 2018 Biomarkers information updated 07 Jun 2018 Bristol-Myers Squibb completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in Argentina, Austria, Belgium, …

Icosapent ethyl, イコサペント酸エチル

It’s only fair to share… Icosapent ethyl 330.5042 , C22H34O2 cas 86227-47-6 / 73310-10-8 ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate Ethyl eicosapentaenoic acid イコサペント酸エチル (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)- [ACD/Index Name] 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- 6GC8A4PAYH 86227-47-6 [RN] all-cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester Timnodonic acid ethyl ester Vascepa 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl …

Revefenacin, ревефенацин , ريفيفيناسين , 瑞维那新 ,

It’s only fair to share… Revefenacin; 864750-70-9; TD-4208; UNII-G2AE2VE07O; G2AE2VE07O; TD-4208; GSK-1160724; 160724; GSK 1160724; TD-4028; YUPELRI Molecular Formula: C35H43N5O4 Molecular Weight: 597.76 g/mol [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate TD-4208 UNII:G2AE2VE07O ревефенацин [Russian] [INN] ريفيفيناسين [Arabic] [INN] 瑞维那新 [Chinese] [INN] Revefenacin is under investigation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Originator Theravance Developer Theravance Biopharma Class Antiasthmatics; Biphenyl compounds; Carbamates; Piperidines Mechanism of Action Muscarinic receptor …

Sarecycline , サレサイクリン

It’s only fair to share…   Sarecycline サレサイクリン MW 487.5024, MF C24H29N3O8 FREE FORM Paratek  INNOVATOR FDA 2018/10/1 APPROVED SEYSARA, ALMIRALL, for the oral treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-[(methoxymethylamino)methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide (4S,4aS,5aR,12aS)-4-(Dimethylamino)-3,10,12,12a-tetrahydroxy-7-{[methoxy(methyl)amino]methyl}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide 1035654-66-0 [RN] FREE FORM 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(methoxymethylamino)methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- 94O110CX2E 9743 P005672,  P 005672 CAS 1035979-44-2 HCl Molecular …

AKN 028

It’s only fair to share… AKN-028 CAS 1175017-90-9 Chemical Formula: C17H14N6 Molecular Weight: 302.33 N-3-(1H-indol-5-yl)-5-pyridin-4-yl-pyrazine-2,3-diamine N2-(1H-indol-5-yl)-6-(pyridin-4-yl)pyrazine-2,3-diamine Originator Swedish Orphan Biovitrum Developer Akinion Pharmaceuticals Class Antineoplastics; Small molecules Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c-kit inhibitors Phase I/II Acute myeloid leukaemia 01 Mar 2016 Akinion Pharmaceuticals terminates phase I/II trial in Acute myeloid leukaemia in Czech Republic, …